Amicus Stock Analysis


USD 10.91  0.21  1.96%   

The latest indifference towards the small price fluctuations of Amicus Therapeutics could raise concerns from shareholders as the firm is trading at a share price of 10.91 on 2,704,376 in volume. The company directors and management did not add any value to Amicus Therapeutics investors in September. However, most investors can still diversify their portfolios with Amicus Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.19. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Amicus Therapeutics partners.
Please check Investing Opportunities.
The Amicus Therapeutics stock analysis report makes it easy to digest most publicly released information about Amicus Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Amicus Stock analysis module also helps to analyze the Amicus Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Amicus Stock Analysis Notes

About 112.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.08. Amicus Therapeutics recorded a loss per share of 1.07. The entity last dividend was issued on the 31st of August 2009. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. To learn more about Amicus Therapeutics call John Crowley at 215 921 7600 or check out

Amicus Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Amicus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Amicus Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Amicus Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 317.83 M. Net Loss for the year was (270.06 M) with profit before overhead, payroll, taxes, and interest of 271.05 M.
Amicus Therapeutics currently holds about 411.2 M in cash with (188.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.47.
Latest headline from Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors -

Amicus Therapeutics Upcoming and Recent Events

Earnings reports are used by Amicus Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amicus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Amicus Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Amicus Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Amicus Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Amicus Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
14th of September 2022
Financial Statements and Exhibits. Other Events
4th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
1st of August 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of June 2022
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of May 2022
Financial Statements and Exhibits. Other Events
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of March 2022
Unclassified Corporate Event. Unclassified Corporate Event
24th of February 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement

Amicus Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Amicus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amicus Therapeutics backward and forwards among themselves. Amicus Therapeutics' institutional investor refers to the entity that pools money to purchase Amicus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Perceptive Advisors LlcCommon Shares26.9 M288.9 M
Avoro Capital Advisors LlcCommon Shares26.8 M287.8 M
Vanguard Group IncCommon Shares25.7 M276.4 M
Redmile Group LlcCommon Shares22.2 M238 M
Blackrock IncCommon Shares20.2 M217.5 M
Morgan StanleyCommon Shares18.3 M196.7 M
Janus Henderson Group PlcCommon Shares16.8 M180.2 M
Note, although Amicus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Amicus Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amicus Therapeutics's market, we take the total number of its shares issued and multiply it by Amicus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Amicus Profitablity

Amicus Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Amicus Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Amicus Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Amicus Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Amicus Therapeutics' profitability requires more research than a typical breakdown of Amicus Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (84.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (68.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.68.

Management Efficiency

The entity has return on total asset (ROA) of (16.59) % which means that it has lost $16.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (110.34) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics management efficiency ratios could be used to measure how well amicus therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 4th of October, Amicus Therapeutics shows the Downside Deviation of 3.19, risk adjusted performance of 0.0224, and Mean Deviation of 2.33. Amicus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Amicus Therapeutics, which can be compared to its rivals. Please confirm Amicus Therapeutics standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if Amicus Therapeutics is priced correctly, providing market reflects its regular price of 10.91 per share. Given that Amicus Therapeutics has jensen alpha of 0.101, we suggest you to validate Amicus Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Amicus Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Simple Moving Average indicator is calculated by adding the closing price of Amicus Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Amicus Therapeutics short-term fluctuations and highlight longer-term trends or cycles.

Amicus Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amicus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amicus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amicus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Amicus Therapeutics Predictive Daily Indicators

Amicus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Amicus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Amicus Therapeutics Forecast Models

Amicus Therapeutics time-series forecasting models is one of many Amicus Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amicus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Amicus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amicus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amicus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Amicus Therapeutics. By using and applying Amicus Stock analysis, traders can create a robust methodology for identifying Amicus entry and exit points for their positions.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people.

Current Amicus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amicus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amicus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Amicus Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Amicus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Amicus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Amicus Therapeutics, talking to its executives and customers, or listening to Amicus conference calls.
Amicus Analyst Advice Details

Amicus Stock Analysis Indicators

Amicus Therapeutics stock analysis indicators help investors evaluate how Amicus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amicus Therapeutics shares will generate the highest return on investment. By understating and applying Amicus Therapeutics stock analysis, traders can identify Amicus Therapeutics position entry and exit signals to maximize returns.
Quick Ratio3.58
Fifty Two Week Low5.91
Revenue Growth18.50%
Shares Short Prior Month29.93M
Average Daily Volume Last 10 Day2.69M
Average Daily Volume In Three Month2.92M
Shares Percent Shares Out7.76%
Gross Margins88.83%
Short Percent Of Float7.81%
Forward Price Earnings-74.57
Float Shares206.69M
Fifty Two Week High12.96
Enterprise Value To Ebitda-13.38
Fifty Day Average11.18
Two Hundred Day Average9.71
Enterprise Value To Revenue8.90
Please check Investing Opportunities. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for analysis

When running Amicus Therapeutics price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Amicus Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.